Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
AI-matched digital twins for MYSTIC trial participants emulated the control arm and overall survival treatment effects.
'These findings highlight the potential for imaging-based digital twins to serve as robust external comparators in oncology clinical trials'— Dr. Omar Khan
MONTREAL, QUEBEC, CANADA, May 15, 2025 / EINPresswire.com / -- Altis Labs, Inc. ('Altis') will present findings at ISPOR 2025 demonstrating how real-world digital twins (rwDTs) can replicate control arm outcomes in AstraZeneca's randomized controlled Phase 3 MYSTIC trial in metastatic non-small cell lung cancer (mNSCLC). These results support the launch of Altis' new product offering that enables clinical development teams to generate external controls with AI applied to comprehensive real-world imaging + clinical + outcomes data.
Altis applied MYSTIC's eligibility criteria to its multimodal real-world data to identify historical patients treated with relevant standard-of-care (SOC) treatment. AI models processed the real-world baseline CT scans and quantified thousands of spatial imaging biomarkers representing total tumor burden, body composition, and other prognostic features. Using baseline imaging characteristics of each MYSTIC subject, 'matching' rwDTs were identified to generate an External Control Arms (ECAs).
AstraZeneca independently evaluated the survival outcomes of the ECAs and compared them to the MYSTIC trial arms, concluding that the ECAs successfully emulated the actual control arm and yielded consistent treatment effect estimates.
'CT Imaging – a 3D reconstruction of the entire patient anatomy – is the most comprehensive data modality already being used in clinical care and oncology trials,' said Felix Baldauf-Lenschen, CEO of Altis. 'It's no surprise that AI applied to this rich data alone can match patients' baseline characteristics to emulate efficacy readouts.'
'These findings highlight the potential for imaging-based digital twins to serve as robust external comparators in oncology clinical trials,' said the presenting author, Dr. Omar Khan, a Clinical Assistant Professor in the Cumming School of Medicine at the University of Calgary and Medical Oncologist at the Arthur J.E. Child Comprehensive Cancer Centre. 'This approach is particularly relevant to help enhance single-arm trials, where comparative evidence is often limited.'
Altis' ECA: A New Tool for Smarter Evidence Generation
The newly launched ECA product enables sponsors to generate external controls using their clinical trial imaging data and Altis' real-world imaging data + associated survival outcomes. Sponsors can use these ECAs in various ways:
• Benchmarking efficacy signal in single-arm trials
• Augmenting a control arm to increase statistical power in RCTs
• Real-world external comparators to inform reimbursement strategy
Altis' models are trained on a proprietary dataset of over 200,000 cancer patients with longitudinal imaging, demographic, diagnostic, treatment, and survival outcomes data, enabling robust matching.
The full results are featured at ISPOR 2025, Poster MSR147: Evaluating Imaging Artificial Intelligence (AI) Matching Real-World Digital Twins (rwDTs) Into an External Control Arm (ECA) for MYSTIC: A Phase 3 Clinical Trial in Metastatic Non-Small Cell Lung Cancer (mNSCLC).
About Altis Labs
Altis Labs is the computational imaging company accelerating clinical trials with AI. Altis has trained proprietary AI models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, and outcomes data. Top 20 biopharmas use Altis' AI models to more confidently analyze data from phase 1-4 clinical trials so that they can bring the most effective novel treatments to patients sooner.
For more information, visit www.altislabs.com, follow @AltisLabs on social media, or email [email protected].
Felix Baldauf-Lenschen
Altis Labs, Inc.
email us here
Visit us on social media:
LinkedIn
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
BMJ Investigation Increases Concerns About Ticagrelor Trials
An investigation by The BMJ is raising fresh concerns about the clinical studies that supported the approval of the antiplatelet drug ticagrelor (Brilinta, AstraZeneca), almost 15 years after the medication was first approved and as generic versions are set to hit the market. Peter Doshi, PhD, a senior editor at The BMJ , previously reported inconsistencies and omissions in data reporting from the 2009 PLATO study, published in The New England Journal of Medicine , which showed ticagrelor was superior to clopidogrel in treating acute coronary syndrome. Now a follow-up investigation of two supporting studies published in Circulation , ONSET/OFFSET and RESPOND, has revealed primary endpoints were reported inaccurately, data were missing from the submission to the US Food and Drug Administration (FDA), and study centers may not have received adequate training. Doshi said the results of his investigations call into question the drug's approval and suggested that it should be revisited. 'The FDA's approval in 2011 went against the evidence according to its reviewers, and now, my investigations into PLATO, ONSET/OFFSET, and RESPOND, suggest that even the data presented to the FDA and reported in The New England Journal of Medicine and Circulation , is not trustworthy,' he told Medscape Medical News. The investigation identified several problems with data integrity in the two trials. The original primary endpoint results for RESPOND, which aimed to test whether ticagrelor could convert nonresponders to clopidogrel into responders, were statistically nonsignificant ( P = .157) but were subsequently reported in Circulation as significant ( P = .005) because of an undeclared change in its primary endpoint definition. For ONSET/OFFSET, which reported ticagrelor provided faster and greater inhibition of platelets than clopidogrel, the investigators now claim several patients were excluded from the analysis. However, those who remained were identified as the 'intention-to-treat' population, implying all patients were included. Implausible data points were also included in the analysis of the primary endpoint but were first transformed through an unpublished data analysis, Doshi claimed. Doshi also gained access to readouts from some of the platelet function test machines used in the trial. He found more than 60 of 282 readings were not present in the datasets submitted to the FDA, and the levels of platelet activity in those readings were significantly higher than those reported in Circulation . Victor Serebruany, MD, from Johns Hopkins University in Baltimore, and one of the more high-profile critics of ticagrelor, told The BMJ the missing readings show 'there are episodes of skyrocketing rebound and profound platelet inhibition after ticagrelor, making patients prone to thrombosis or bleeding. If doctors had known what happened in these trials, they would never have started using ticagrelor.' The investigation also revealed oddities around the authorship of the publications. One active trial investigator was never identified as a study author, while one author told The BMJ he was not involved in the trial. The BMJ states that AstraZeneca, the journal Circulation , and many of the original investigators either declined to comment on the new claims or were unreachable. Ticagrelor has been under fire since the beginning. The drug failed in its first bid for FDA approval and was the subject of an investigation by the US Department of Justice in 2013 at the urging of Serebruany. That investigation was closed in 2014 with no further action. A review of several major trials of ticagrelor by Eric Bates, MD, professor of internal medicine at the University of Michigan in Ann Arbor, Michigan, and a co-author of the US guidelines that recommend ticagrelor, concluded 'the clinical conventional wisdom and clinical trial guideline support for…ticagrelor compared with clopidogrel may be overemphasized.' Bates is now calling for a review of ticagrelor's recommendation in guidelines, according to the earlier The BMJ report.
Yahoo
2 days ago
- Yahoo
IonQ (NYSE:IONQ) Announces Quantum Breakthrough in Protein Folding and Computation
IonQ recently announced a significant achievement with Kipu Quantum, solving the most complex protein folding problem on a quantum computer. This breakthrough likely contributed to the company's impressive 87% share price gain last quarter. The successful partnership with AstraZeneca and others to accelerate drug development, and collaborations with Toyota Tsusho and KISTI, bolster its global presence. Additionally, positive earnings projections and leadership changes further supported market confidence. While the broader market saw a modest yearly gain, IonQ's advancements in quantum computing positioned it to significantly outperform industry trends during the quarter. We've identified 5 warning signs for IonQ (1 is significant) that you should be aware of. AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Looking at the broader picture, investors in IonQ have seen extraordinary returns over a three-year period, with the company's total shareholder returns climbing by over 694%. This performance towers above the US Tech industry's past year return of -9% and the general US market, which returned 9.9% over the same period. Such a return underscores the market's current enthusiasm for IonQ's innovative breakthroughs in quantum computing, particularly its solutions like the recent protein folding achievements which hold great promise for drug discovery applications. The company's recent advancements and strategic partnerships suggest strong potential for future revenue growth, projected at 41% per year. However, IonQ remains unprofitable, with its Q1 earnings reflecting a net loss of US$32.25 million, and forecasts indicating ongoing losses in the upcoming years. Analyst consensus places a fair value target at US$43, slightly above the current share price, indicating a restrained outlook relative to recent market exuberance. Nevertheless, IonQ maintains a strong trajectory in revenue growth, supported by their global expansion and successful collaborations with industry giants like AstraZeneca, which could bolster its future market position. Upon reviewing our latest valuation report, IonQ's share price might be too optimistic. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IONQ. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Yahoo
IonQ (NYSE:IONQ) Announces Quantum Breakthrough in Protein Folding and Computation
IonQ recently announced a significant achievement with Kipu Quantum, solving the most complex protein folding problem on a quantum computer. This breakthrough likely contributed to the company's impressive 87% share price gain last quarter. The successful partnership with AstraZeneca and others to accelerate drug development, and collaborations with Toyota Tsusho and KISTI, bolster its global presence. Additionally, positive earnings projections and leadership changes further supported market confidence. While the broader market saw a modest yearly gain, IonQ's advancements in quantum computing positioned it to significantly outperform industry trends during the quarter. We've identified 5 warning signs for IonQ (1 is significant) that you should be aware of. AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Looking at the broader picture, investors in IonQ have seen extraordinary returns over a three-year period, with the company's total shareholder returns climbing by over 694%. This performance towers above the US Tech industry's past year return of -9% and the general US market, which returned 9.9% over the same period. Such a return underscores the market's current enthusiasm for IonQ's innovative breakthroughs in quantum computing, particularly its solutions like the recent protein folding achievements which hold great promise for drug discovery applications. The company's recent advancements and strategic partnerships suggest strong potential for future revenue growth, projected at 41% per year. However, IonQ remains unprofitable, with its Q1 earnings reflecting a net loss of US$32.25 million, and forecasts indicating ongoing losses in the upcoming years. Analyst consensus places a fair value target at US$43, slightly above the current share price, indicating a restrained outlook relative to recent market exuberance. Nevertheless, IonQ maintains a strong trajectory in revenue growth, supported by their global expansion and successful collaborations with industry giants like AstraZeneca, which could bolster its future market position. Upon reviewing our latest valuation report, IonQ's share price might be too optimistic. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IONQ. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
